Tear Metabolomics in Dry Eye Disease: A Review.
Mazyar YazdaniKatja Benedikte Prestø ElgstøenHelge RootweltAboulghassem ShahdadfarØygunn Aass UtheimTor Paaske UtheimPublished in: International journal of molecular sciences (2019)
Dry eye disease (DED) is a multifactorial syndrome that can be caused by alteration in the quality or quantity of the precorneal tear film. It is considered one of the most common ocular conditions leading patients to seek eye care. The current method for diagnostic evaluations and follow-up examinations of DED is a combination of clinical signs and symptoms determined by clinical tests and questionnaires, respectively. The application of powerful omics technologies has opened new avenues toward analysis of subjects in health and disease. Metabolomics is a new emerging and complementary research discipline to all modern omics in the comprehensive analysis of biological systems. The identification of distinct metabolites and integrated metabolic profiles in patients can potentially inform clinicians at an early stage or during monitoring of disease progression, enhancing diagnosis, prognosis, and the choice of therapy. In ophthalmology, metabolomics has gained considerable attention over the past decade but very limited such studies have been reported on DED. This paper aims to review the application of tear metabolomics in DED.
Keyphrases
- end stage renal disease
- mass spectrometry
- early stage
- ejection fraction
- healthcare
- chronic kidney disease
- newly diagnosed
- palliative care
- stem cells
- squamous cell carcinoma
- machine learning
- depressive symptoms
- bone marrow
- risk assessment
- lymph node
- climate change
- gold nanoparticles
- sleep quality
- reduced graphene oxide
- decision making
- replacement therapy
- sentinel lymph node
- locally advanced
- neoadjuvant chemotherapy